Boscia JA, Pudi KK, Zvarich MT et al. (2012) Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. Clinical Therapeutics 34: 1655–66

Dransfield MT, Bourbeau J, Jones PW et al. (2013) Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. The Lancet Respiratory Medicine 1: 210–23 doi: 10.1016/s2213-2600(13)70040-7

Kerwin EM, Scott-Wilson C, Sanford L et al. (2013) A randomised trial of fluticasone furoate/vilanterol (50/25 microgram; 100/25 microgram) on lung function in COPD. Respiratory Medicine 107: 560–9

Martinez FJ, Boscia J, Feldman G et al. (2013) Fluticasone furoate/vilanterol (100/25 microgram; 200/25 microgram) improves lung function in COPD: a randomised trial. Respiratory Medicine 107: 550–9

National Institute for Health and Clinical Excellence (2010) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). NICE clinical guideline 101

National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease. NICE Pathway [online; accessed 9 May 2013]

US National Institute of Health (2012) Identifier: NCT01342913 [online; accessed 23 April 2013]